The average remission rate across trials (n=3) for SRI and non-active comparison conditions were 47% and 22%, respectively. A random effects meta-analysis identified a moderate effect for SRIs relative to comparison conditions (RR=2.06, 95% CI: 1.03, 4.13, z=2.05 p=0.04) with minimal heterogeneity [Q(2)=3.66, p=0.16, I2=45.35%] (Figure 4). The NNT for SRI symptom remission was five. Visual inspection of the funnel plot and Egger’s test for bias indicated that publication bias was not present (t=2.25, p=0.27). All trials with treatment response data used a placebo control condition.
